A Phase 3 interventional study of BiominF and Novamin in White Spot Lesion of Tooth, sponsored by Rania Salah. Completed at 1 site in Egypt. Open to participants aged 14 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-19.
Sponsored by Rania Salah · Phase 3, Interventional, and Treatment
the aim of this study is to evaluate the effectiveness of BiominF® and Novamin® in comparison to Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) in the treatment of enamel white spot lesions
Exclusion Criteria:
Test group
Drug: BiominF
Test group
Drug: Novamin
Control group
Drug: CPP-ACP
in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
applied in accordance with the manufacturer's specifications
Change in White spot lesions dimension
Quantified using computer-assisted analysis based on digital intraoral photographs
Time frame: 6 months: (Baseline, 1 week, 1 month, 3 months, 6 months)
change in lesion fluorescence
evaluated using diode laser fluorescence device (Diagnodent)
Time frame: 6 months: (Baseline, 1 week, 1 month, 3 months, 6 months)
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.